Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cosentyx Clear all
Completed Phase 3 Interventional Results available

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

NCT03478787
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab, secukinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

NCT03556202
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

NCT01365455
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, placebo to secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 4 Interventional

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

NCT04535999
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab Auto-Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 10, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

NCT06751238
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

NCT02008916
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
secukinumab (AIN457), placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

NCT03344640
View directory record Official record
Conditions
Tendinopathy
Interventions
secukinumab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • La Mesa, California • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

NCT01095250
View directory record Official record
Conditions
Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Beverly Hills, California • Cambridge, Massachusetts • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

NCT01807520
View directory record Official record
Conditions
Moderate to Severe Nail Psoriasis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

NCT02294227
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Mesa, Arizona • Upland, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038
View directory record Official record
Conditions
Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

NCT00809159
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Not listed Phase 4 Interventional

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

NCT03307447
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Secukinumab
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Secukinumab for the Treatment of Alopecia Areata

NCT02599129
View directory record Official record
Conditions
Alopecia Areata
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Recruiting Phase 1 Interventional

IL-17 Blockade to Decrease irAEs (REPLAY)

NCT07237594
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Secukinumab Injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 3:33 AM EDT